What is the recommended further management for an alcoholic cirrhosis patient with portal hypertension and ascites who has an INR of 1.3?

Management of Alcoholic Cirrhosis with Portal Hypertension and Ascites (INR 1.3, PT 18)

Start combination diuretic therapy with spironolactone 100 mg plus furosemide 40 mg once daily in the morning, along with dietary sodium restriction to 88 mmol/day (approximately 2 g/day), and perform diagnostic paracentesis immediately to rule out spontaneous bacterial peritonitis. 1, 2, 3

Immediate Diagnostic Steps

• Perform diagnostic paracentesis as soon as possible to exclude spontaneous bacterial peritonitis (SBP) and confirm the diagnosis of portal hypertension-related ascites. 3
• Send ascitic fluid for cell count with differential, serum-ascites albumin gradient (SAAG), Gram stain, and culture. 3
• A SAAG ≥1.1 g/dL confirms portal hypertension as the cause of ascites. 2
• Check baseline serum electrolytes (sodium, potassium), creatinine, BUN, and albumin before initiating diuretics. 1

First-Line Pharmacologic Management

Diuretic Therapy

The INR of 1.3 and PT of 18 do not contraindicate oral diuretic therapy or require correction before starting treatment. 2

• Initiate combination therapy with spironolactone 100 mg + furosemide 40 mg once daily rather than sequential monotherapy, as this achieves faster resolution of ascites (76% vs 56%) and lower rates of hyperkalemia (4% vs 18%). 1, 4
• This 100:40 mg ratio should be maintained during dose escalation. 1
• Titrate both agents simultaneously every 3–5 days if weight loss is inadequate (<0.5 kg/day without peripheral edema), up to maximum doses of spironolactone 400 mg and furosemide 160 mg daily. 1, 2
• Target weight loss is approximately 0.5 kg/day in patients without peripheral edema; no strict limit applies when edema is present. 1

Dietary Sodium Restriction

• Restrict dietary sodium to 88 mmol/day (approximately 2 g/day or 5 g salt/day). 2, 3
• Provide education and referral to a dietitian for dietary management. 3

Monitoring Protocol

First Week

• Check serum potassium, creatinine, sodium, and BUN at week 1. 1
• Monitor blood pressure, body weight, and vital signs. 1

Weeks 2–4

• Repeat electrolyte panel every 5–7 days until values stabilize. 1
• Assess 24-hour urine sodium (target >78 mmol/day) or spot urine Na/K ratio (target >1) to confirm adequate natriuresis. 1

Months 1–3

• Check renal function and electrolytes at 1,2, and 3 months. 1

After 3 Months

• If stable, continue monitoring every 3–6 months. 1

Electrolyte-Related Dose Adjustments

• Hyperkalemia (K ≥6.0 mmol/L): Stop spironolactone immediately. 1
• Hyperkalemia (K 5.5–5.9 mmol/L): Halve spironolactone dose. 1
• Hypokalemia: Temporarily hold furosemide, particularly in alcoholic hepatitis where potassium depletion is common. 1
• Hyponatremia (Na <125 mmol/L): Reduce or stop diuretics and implement fluid restriction to 1–1.5 L/day. 1, 3
• Acute kidney injury or creatinine rise ≥50% (or absolute value >266 µmol/L): Suspend or adjust diuretic therapy. 1

Additional Management Considerations

Portal Hypertension Prevention

• Consider non-selective beta-blockers (carvedilol or propranolol) to prevent variceal bleeding and reduce risk of further decompensation (16% vs 27% over 3 years). 4
• Perform upper endoscopy to screen for esophageal varices unless platelets >150,000 and liver stiffness <20 kPa (Baveno criteria). 2
• Refractory ascites is not a contraindication to beta-blockers, but monitor closely for hypotension or renal dysfunction. 2

Large-Volume Paracentesis

• If ascites is tense or causing respiratory compromise, perform therapeutic paracentesis. 2, 3
• Administer 20–25% albumin at 8 g per liter of ascites removed when >5 L is drained to prevent post-paracentesis circulatory dysfunction. 2, 3
• For volumes <5 L, consider albumin in patients with hypotension, renal insufficiency, or electrolyte abnormalities. 3

Refractory Ascites Management

• If ascites becomes refractory (fails to respond to maximum diuretic doses or recurs rapidly after paracentesis), consider: 2, 3
  • Transjugular intrahepatic portosystemic shunt (TIPS) in well-selected patients, which reduces further decompensation and improves survival. 2, 5
  • TIPS should be used cautiously if age >70 years, bilirubin >50 μmol/L, platelets <75×10⁹/L, MELD ≥18, or active hepatic encephalopathy. 2
  • Serial large-volume paracentesis with albumin replacement remains the standard for patients not suitable for TIPS. 2, 3

Liver Transplantation Evaluation

• All patients with ascites should be evaluated for liver transplantation eligibility, as the median survival after ascites onset is approximately 1.1 years. 4, 3
• Patients with refractory ascites should be considered for transplant evaluation regardless of MELD score. 3

Critical Safety Warnings

• Use only oral diuretics—intravenous furosemide is associated with acute GFR reduction and azotemia in cirrhosis due to preserved oral bioavailability. 1
• Avoid NSAIDs, which blunt natriuretic response and increase hyperkalemia risk. 1
• If tender gynecomastia develops from spironolactone, replace with amiloride 10–40 mg (less potent but fewer anti-androgen effects). 1
• Address triggers of decompensation including ongoing alcohol use, infections, gastrointestinal bleeding, and hepatotoxic medications. 3, 2